Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-718-4 | CAS number: 109-92-2
Endpoint summary
Administrative data
Description of key information
The oral LD50 in rats was 6150 mg/kg bw.
The LC50 (4 h) in rats is > 21 mg/L or 7200 ppm.
The dermal LD50 in rabbits is >15100 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 6 150 mg/kg bw
Additional information
Acute toxicity data in experimental animals
Oral
The LD50 in male Wistar rats was 8.16 mL/kg bw corresponding to 6150 mg/kg bw; the post exposure observation period was 14 days (Smyth et al., 1969; limited documentation).
Inhalation
In the Limit test (BASF 1988) in 5 male and 5 female Wistar rats (according to OECD Guideline 403) no mortality was found but clinical signs (sedation) at a concentration of 21 mg/L (7200 ppm) and an exposure duration of 4 h. Apathy, closed lids and depressed breathing were noted during exposure, these clinical signs were absent the following day. No effects were detected at necropsy 2 weeks after exposure.
Promising anaesthetic properties of EVE were noted in various species. Narcotic potency of EVE was larger than that of diethylether (Krantz et al., 1947).
Dermal
In 4 male New Zealand White rabbits the maximum applied dose volume of 20 mL/kg bw did not induce lethal effects after an exposure period of 24 h (occlusive; post exposure period 14 days), therefore the LD50 is >20 mL/kg bw, i.e. > 15080 mg/kg bw (Smyth et al., 1969; limited documentation).
Acute inhalation toxicity in humans
In a female volunteer narcosis was induced by the open drop method. The blood pressure and pulse were not significantly altered. She reported no irritation of the respiratory tract after acute inhalation of presumably saturated vapour (Krantz et al., 1947).
Side effects of EVE in anaesthesia like nausea, vomiting, and ECG changes were documented during and after anaesthesia (Sadove et al., 1955); in another study (Dornette et al., 1955) also obstruction, hypoxia, coughing, deficient relaxation as well as fatal cases (respiratory or ciculatory arest) were reported.
Justification for classification or non-classification
Classification for acute toxicity is not warranted according to the criteria of EU Directive 67/548/EEC and EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
EVE is classified with H336 ("May cause drowsiness or dizziness") based on human data (abandoned historical use of EVE as human anesthetic agent).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
